An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Jan 2025 According to an Antengene Corporation media release, the enrollment of gastric cancer patients for dose optimization and patients with other solid tumors is ongoing in China and Australia.
22 Jan 2025 Results (As of 22 Nov 2024) presented in an Antengene Corporation media release
22 Jan 2025 According to an Antengene Corporation media release, latest data from this phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advanced or metastatic gastric cancer presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025), Thurs, Jan 23, 2025 at 11:30 AM-1:00 PM (Pacific time).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com